DIVERSIFIED PIPELINE
DISCOVERED USING PHARMA.AI
DISCOVERED USING PHARMA.AI
INNOVATIVE AND ACCELERATED INTERNAL DRUG CANDIDATES
- 31Total Number
of Programs - 21Preclinical Candidates Nominated from 2021
- 9Preclinical Candidates Nominated in 2022
- 10Pipelines received
IND approval
Over 20 additional newly initiated programs in the discovery stage
Available for licensing
Hit to Lead
IND-enabling
IND-clearance
Phase 1
INDICATION
Lead Opt.
Target ID
Phase IIa Completed
with good tolerability and safety. Dose dependent FVC improvements observed.
Phase 2a
Lead Optimization
Phase 2a
IND-enabling
Phase 1
Programs below progressed beyond early pre-clinical. More programs are available under CDA.
Contact bd@insilicomedicine.com for partnering opportunities
COLLABORATIONS
AND PARTNERSHIPS
AND PARTNERSHIPS
The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of Biology42, Chemistry42, and Medicine42.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
TNIK
TNIK Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
ENPP1
Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor: Treating anti-PD-1/-L1 resistant cancers
DGKA
Diacylglycerol kinase A (DGKA) Inhibitor: Treating solid tumors in combination with checkpoint inhibitor
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitor: Treating Tumors by Induction of BRCAness
TEAD
Pan-TEAD Inhibitor: Treating Mesothelioma, and Solid Tumors
FGFR2/3
FGFR2/3 Dual Inhibitor: Treatment of Solid Tumors
KIF18A
KIF18A Inhibitor: Treating chromosomally unstable cancers with TP53 mutations
WRN
WRN Inhibitor: Treating microsatellite instability-high (MSI-H) cancers